Search Results
May 18, 2026, 08:00 ET Bang Energy Launches American Berry - A Bold New Flavor Celebrating 250 Years of America
experimentation.Like Purple Haze, Lime Pop Drop, Peach Mango and the rest of the Bang family, each 16-oz. can of American Berry energizes with 300 mg of caffeine and contains zero sugar and zero calories, along with Ultra CoQ10 and essential aminos, powering the "READY SET BANG" ethos.Whether
More news about: Bang Energy
May 18, 2026, 08:00 ET U.S. FDA Accepts Viatris New Drug Application for Fast-Acting Meloxicam for the Treatment of Moderate-to-Severe Acute Pain
(NCT06215820).Both Phase 3 trials evaluated the efficacy and safety of fast-acting meloxicam versus placebo and included an opioid arm (tramadol 50mg q6h) to confirm the sensitivity of the pain model. The primary endpoint in both trials was defined by the Sum of Pain Intensity Difference (SPID) based
More news about: Viatris Inc.
May 18, 2026, 08:00 ET Astellas to Present Data on Long-Term Outcomes and Clinical Use of Its Portfolio Across Disease Stages at ASCO 2026
evaluation. Closely monitor blood glucose levels in patients with, or at risk for, diabetes mellitus or hyperglycemia. If blood glucose is elevated (>250 mg/dL), withhold PADCEV.Pneumonitis/Interstitial lung disease (ILD) Severe, life-threatening or fatal pneumonitis/ILD occurred in patients treated
More news about: Astellas Pharma Inc.
May 18, 2026, 07:32 ET Samson Clinical Announces Last Patient Last Visit in its Pivotal Phase III Study of Sublingual Minoxidil for Male Androgenetic Alopecia
results are expected in Q2 2026.SAM-002 is a 24-week, multicentre, double-blind, placebo-controlled study investigating a rapid dissolving 2.5 mg minoxidil tablet, administered sublingually twice daily. The primary endpoint is the mean change in the Target Area Hair Count.Sublingual minoxidil
More news about: Samson Clinical Operations Pty Ltd
May 18, 2026, 07:00 ET Triquetra Health Launches FolinicActive™--First Multi-Pathway Active Folate with Complete Tri-Cofactor System
daily) and a vegan capsule (60 count, 1 capsule daily). Both deliver identical active ingredients at identical doses—1 mg folinic acid, 1,000 mcg B-12 tri-blend, 5 mg P-5-P, and 2 mg R-5-P—enabling flexible format selection without any change in formulation. The liquid and capsule products are manufactured
More news about: Triquetra Health LLC
May 18, 2026, 07:00 ET Triquetra Health Launches FolinicActive™ Adult Liquid--First Multi-Pathway Active Folate with Complete Tri-Cofactor System
Liquid delivers 1 mg folinic acid (as calcium folinate) per 0.50 mL serving alongside the Complete Tri-Cofactor System: 1,000 mcg Vitamin B-12 as a tri-blend (80% methylcobalamin, 10% adenosylcobalamin, 10% hydroxocobalamin), 5 mg active B-6 as pyridoxal-5′-phosphate (P-5-P), and 2 mg active B-2 as riboflavin-5′-phosphate
More news about: Triquetra Health LLC
May 18, 2026, 07:00 ET Apnimed Announces Publication of its Phase 3 SynAIRgy Trial of AD109 for Obstructive Sleep Apnea in the American Journal of Respiratory and Critical Care Medicine
of sleep-related breathing diseases, today announced the simultaneous publication of two peer-reviewed articles on AD109 (aroxybutynin 2.5 mg/atomoxetine 75 mg), an investigational, once-daily oral pill taken at bedtime designed to improve oxygenation and target the neuromuscular root cause of obstructive
More news about: Apnimed, Inc.
May 18, 2026, 07:00 ET Triquetra Health Launches Instant Aminos--First Free-Form EAA Tablets Delivering All 9 Essential Amino Acids with Zero Bloating
blender, no bloating means it actually fits your life. This is protein support built around how people want to live."Instant Aminos features a 4,000mg Amino Acid Complex per 4-tablet serving, including L-Leucine, L-Lysine Acetate, L-Valine, L-Isoleucine, L-Threonine, L-Phenylalanine, L-Methionine,
More news about: Triquetra Health LLC
May 18, 2026, 03:08 ET Unionfab verkürzt die Fertigungszeit für Metallteile in Kleinserien von 30 Tagen auf nur noch 5 Tage
Oberflächenqualität gewährleistet bleiben.Unionfab unterstützt verschiedene Materialien in Industriequalität, darunter Edelstahl (316L, 17-4PH), Aluminium (AlSi10Mg, Al6061, Al901X), Titan (TC4), CuCrZr und Inconel (625, 718) usw. Die selbst entwickelte hochfeste Aluminiumlegierung Al901X in Luft- und Raumfahrtqualität
More news about: Unionfab
May 18, 2026, 03:08 ET Unionfab Reduces Low-Volume Metal Parts Production from 30 Days to as Fast as 5 Days
density and consistent surface quality.Unionfab supports various industrial-grade materials, including stainless steel (316L, 17-4PH), aluminum (AlSi10Mg, Al6061, Al901X), titanium (TC4), CuCrZr and Inconel (625, 718) etc. Its self-developed aerospace-grade high-strength aluminum alloy Al901X combines
More news about: Unionfab
May 17, 2026, 20:03 ET Harbour BioMed Announces Promising Preclinical Data for LET003, Its First AI-Enabled Drug Candidate
dose levels (5 mg/kg, 10 mg/kg, and 15 mg/kg). The results showed that both molecules contributed more to the increase in lean mass than to fat accumulation. After three weeks of treatment, LET003 at 5 mg/kg achieved lean mass-promoting effects comparable to those observed with 15 mg/kg bimagrumab. These
More news about: Harbour BioMed
May 15, 2026, 07:36 ET Keenova Announces Newly Updated Peyronie's Disease Study Results at American Urology Association Meeting
patients taking low-dose aspirin, eg, up to 150 mg per day) were excluded from participating in these studies. Therefore, the efficacy and safety of XIAFLEX in patients receiving anticoagulant medications (other than low-dose aspirin, eg, up to 150 mg per day) within 7 days prior to XIAFLEX administration
More news about: Keenova Therapeutics
May 15, 2026, 07:06 ET Racura Oncology Announces Positive Safety Review Committee Recommendation in ongoing CPACS Clinical Trial
the SRC recommended that the study continue, noting no safety concerns in patients treated with 40mg/m2 of RC220 as monotherapy, or 40mg/m2 of RC220 in combination with 60mg/m2 of doxorubicin, in the first patient cohort of this groundbreaking trial."The SRC's
More news about: Racura Oncology
May 14, 2026, 19:03 ET SN BioScience Doses First Patient in Phase 1b/2 Clinical Trial of 'SNB-101'
three sequential stages: a Phase 1b dose-escalation phase using a 3+3 design to determine the Maximum Tolerated Dose (MTD) at dose levels of 50–70 mg/m², followed by a two-part Phase 2 consisting of Phase 2a and Phase 2b. Phase 2a will conduct dose optimization to identify the optimal therapeutic dose,
More news about: SN BioScience Inc
May 14, 2026, 18:01 ET ESGE Days 2026: Endoscopic procedure associated with greater short-term weight loss than oral semaglutide, study finds
evaluated outcomes at six months.Patients undergoing ESG achieved a mean total body weight loss of 12.7%, compared with 8.7% in those receiving 14mg of oral semaglutide, corresponding to a mean difference of approximately 4.0% (p=0.0001). This difference remained significant after adjustment for baseline
More news about: ESGE Days 2026
May 14, 2026, 18:01 ET ESGE-Tage 2026: Endoskopisches Verfahren führt kurzfristig zu größerem Gewichtsverlust als orales Semaglutid, so eine Studie
Patienten, die sich der ESG unterzogen, wurde ein mittlerer Gesamtkörpergewichtsverlust von 12,7 % erreicht, verglichen mit 8,7 % bei den Patienten, die 14 mg orales Semaglutid erhielten, was einem mittleren Unterschied von etwa 4,0 % entspricht (p=0,0001). Dieser Unterschied blieb auch nach Anpassung an die
More news about: ESGE Days 2026
May 14, 2026, 18:01 ET Journées ESGE 2026 : Une étude révèle que la procédure endoscopique est associée à une perte de poids à court terme plus importante que le semaglutide oral
résultats à six mois.Les patients soumis à l'ESG ont perdu en moyenne 12,7 % de leur poids corporel total, contre 8,7 % chez ceux recevant 14 mg de semaglutide oral, ce qui correspond à une différence moyenne d'environ 4,0 % (p=0,0001). Cette différence est restée significative après ajustement
More news about: ESGE Days 2026
May 14, 2026, 18:01 ET ESGE Days 2026: el procedimiento endoscópico se asocia con una mayor pérdida de peso que la semaglutida oral
pacientes sometidos a ESG lograron una pérdida de peso corporal total promedio del 12,7 %, en comparación con el 8,7 % en aquellos que recibieron 14 mg de semaglutida oral, lo que corresponde a una diferencia promedio de aproximadamente el 4,0 % (p = 0,0001). Esta diferencia se mantuvo significativa
More news about: ESGE Days 2026
May 14, 2026, 16:23 ET Apotex launches Apo‑Semaglutide Injection™, a generic equivalent of Ozempic®, in Canada
Apo‑Semaglutide Injection is approved in 2 mg and 4 mg prefilled pen formats, providing:0.25 mg or 0.5 mg doses (2 mg pen; 0.68 mg/mL) 1 mg doses (4 mg pen; 1.34 mg/mL)Apo-Semaglutide Injection™ is administered using a prefilled
More news about: Apotex Inc.
May 14, 2026, 16:05 ET MetaVia Reports First Quarter 2026 Financial Results and Provides Corporate Update
48 mg Phase 1 Data Demonstrated Potential Best-in-Class Profile for DA-1726 with 9.1% Weight Loss, Improved Glucose Control and Direct Liver Benefit Key Milestone Achieved with Dosing of the First Patient in Phase 1 Part 3 16-Week Titration Study Evaluating 48 mg (1-Step)
More news about: MetaVia Inc.
May 14, 2026, 08:00 ET Natrol® Launches Ultra Sleep and Ultra Energy; Partners with Calm and Michelle Monaghan to Support the Full Sleep Cycle and 24-Hour Wellness
and REM sleep, formulated with†:5mg Melatonin: The #1 doctor recommended ingredient for sleep3 that works to help you fall asleep faster and stay asleep longer†100mg of GABA: Promotes relaxation by signaling the brain to calm down†Dream
More news about: Natrol
May 14, 2026, 07:32 ET Delta Beverages Contributes to National Advocacy Effort Supporting Hemp Beverage Regulation
into life's meaningful moments. Delta's beverages are crafted for every vibe and tolerance level, available in three precisely dosed options - 5mg, 10mg, and 20mg of premium hemp-derived THC - and eight bold, refreshing flavors. Delta is third-party tested and committed to quality, consistency, and responsible
More news about: Delta Beverages
May 14, 2026, 07:30 ET Galmed Announces Results from First-in-Man Pharmacokinetics Study of Oral Formulation of Aramchol Meglumine (AM); 400mg AM Increases Bioavailability by ~500% in Comparison to Aramchol Free Acid (AA) 300mg
once daily that produces similar exposure to Aramchol from 300mg Aramchol free acid (AA) tablets dosed twice daily. Single doses of AM granules for oral suspension of 400 mg and 200mg were evaluated and compared to AA 300mg tablet. The study demonstrated that the bioavailability of Aramchol
More news about: Galmed Pharmaceuticals Ltd.
May 14, 2026, 07:30 ET Karyopharm Reports First Quarter 2026 Financial Results and Completion of Phase 3 Endometrial Cancer Trial Enrollment
(ASCO) Annual Meeting.Reported topline results from the Phase 3 SENTRY trial, a randomized, double-blind trial evaluating 60 mg selinexor in combination with ruxolitinib in frontline myelofibrosis compared to ruxolitinib alone (n=353). The trial met the first co-primary endpoint
More news about: Karyopharm Therapeutics Inc.
May 13, 2026, 16:05 ET Nuvation Bio to Collaborate with Thermo Fisher Scientific for U.S.-Based Manufacturing of IBTROZI® for ROS1-Positive Non-Small Cell Lung Cancer
or fatal ILD or pneumonitis can occur. ILD/pneumonitis occurred in 2.3% of patients, including 1.1% Grade 3/4. One fatal ILD case occurred at the 400 mg daily dose. Median time to first onset of ILD/pneumonitis was 3.8 months (range: 12 days to 11.8 months). ILD/pneumonitis led to dose interruption
More news about: Nuvation Bio Inc.